BioCentury | Mar 23, 2009
Company News

MediVas, Royal DSM deal

...Royal DSM received an exclusive, worldwide license to develop and commercialize MediVas' polymer-based drug delivery system...
...Trancerta Drug Delivery platform, which is a controlled-release, bipolymer technology. Financial terms were not disclosed. MediVas LLC...
BioCentury | Sep 29, 2008
Product Development

Ophthalmic deals

...exclusive worldwide rights to Pfizer's azithromycin to treat eye infections Jan 07 MediVas/Pfizer (NYSE:PFE) Undisclosed MediVas...
BioCentury | Apr 9, 2007
Company News

MediVas, Merck deal

...an undisclosed milestone payment from MRK under a deal in which the companies are applying MediVas'...
...biologics from MRK (see BioCentury, Feb. 5). The payment was triggered by an undisclosed event. MediVas LLC...
BioCentury | Feb 12, 2007
Company News

MediVas, Nautilus Biotech, Wyeth deal

...payment and R&D funding and is eligible for milestones and royalties. Under a separate deal, MediVas...
...formulations of WYE's recombinant hemophilia products. WYE will research, develop, manufacture and market resulting products. MediVas...
...eligible for milestones and royalties. WYE markets BeneFIX Coagulation Factor IX to treat hemophilia B. MediVas LLC...
BioCentury | Feb 12, 2007
Product Development

Doubling up for half-life

...ongoing Factor IX project, but declined to disclose its development status. In WYE’s second deal, MediVas LLC...
...delivery system to WYE’s recombinant hemophilia products. MediVas is eligible for milestone payments and royalties. MediVas’...
BioCentury | Feb 6, 2007
Company News

Wyeth in trio of deals

...and R&D funding, and is eligible for milestones, plus royalties. In the second hemophilia deal, MediVas...
...for recombinant hemophilia products. WYE will research, develop, manufacture and market any resulting products, and MediVas...
BioCentury | Feb 5, 2007
Company News

MediVas, Merck deal

...The companies will apply MediVas’ polyesteramide (PEA) copolymer delivery technology to undisclosed MRK oral biologics. MRK...
...MRK also has an exclusive option to use the technology with additional undisclosed oral biologics. MediVas...
...upfront payment and is eligible for milestones and research funding. Further details were not disclosed. MediVas LLC...
BioCentury | Jan 29, 2007
Company News

MediVas, Pfizer deal

...technology to undisclosed PFE compounds to treat ophthalmic diseases. MediVas received an undisclosed upfront payment. MediVas LLC...
BioCentury | Jan 15, 2007
Company News

MediVas, PacificGMP Inc. deal

...PacificGMP partnered to develop a commercial scale production process for MediVas' subunit vaccines, which use MediVas'...
...virus infection are expected to enter the clinic this year. Financial terms were not disclosed. MediVas LLC...
BioCentury | Oct 23, 2006
Clinical News

MediVas preclinical data

...hemagglutinin (HA) and nucleoprotein (NP) from the A/Vietnam/1203/2004 virus. MediVas LLC , San Diego, Calif. Product: MediVas...
Items per page:
1 - 10 of 13
BioCentury | Mar 23, 2009
Company News

MediVas, Royal DSM deal

...Royal DSM received an exclusive, worldwide license to develop and commercialize MediVas' polymer-based drug delivery system...
...Trancerta Drug Delivery platform, which is a controlled-release, bipolymer technology. Financial terms were not disclosed. MediVas LLC...
BioCentury | Sep 29, 2008
Product Development

Ophthalmic deals

...exclusive worldwide rights to Pfizer's azithromycin to treat eye infections Jan 07 MediVas/Pfizer (NYSE:PFE) Undisclosed MediVas...
BioCentury | Apr 9, 2007
Company News

MediVas, Merck deal

...an undisclosed milestone payment from MRK under a deal in which the companies are applying MediVas'...
...biologics from MRK (see BioCentury, Feb. 5). The payment was triggered by an undisclosed event. MediVas LLC...
BioCentury | Feb 12, 2007
Company News

MediVas, Nautilus Biotech, Wyeth deal

...payment and R&D funding and is eligible for milestones and royalties. Under a separate deal, MediVas...
...formulations of WYE's recombinant hemophilia products. WYE will research, develop, manufacture and market resulting products. MediVas...
...eligible for milestones and royalties. WYE markets BeneFIX Coagulation Factor IX to treat hemophilia B. MediVas LLC...
BioCentury | Feb 12, 2007
Product Development

Doubling up for half-life

...ongoing Factor IX project, but declined to disclose its development status. In WYE’s second deal, MediVas LLC...
...delivery system to WYE’s recombinant hemophilia products. MediVas is eligible for milestone payments and royalties. MediVas’...
BioCentury | Feb 6, 2007
Company News

Wyeth in trio of deals

...and R&D funding, and is eligible for milestones, plus royalties. In the second hemophilia deal, MediVas...
...for recombinant hemophilia products. WYE will research, develop, manufacture and market any resulting products, and MediVas...
BioCentury | Feb 5, 2007
Company News

MediVas, Merck deal

...The companies will apply MediVas’ polyesteramide (PEA) copolymer delivery technology to undisclosed MRK oral biologics. MRK...
...MRK also has an exclusive option to use the technology with additional undisclosed oral biologics. MediVas...
...upfront payment and is eligible for milestones and research funding. Further details were not disclosed. MediVas LLC...
BioCentury | Jan 29, 2007
Company News

MediVas, Pfizer deal

...technology to undisclosed PFE compounds to treat ophthalmic diseases. MediVas received an undisclosed upfront payment. MediVas LLC...
BioCentury | Jan 15, 2007
Company News

MediVas, PacificGMP Inc. deal

...PacificGMP partnered to develop a commercial scale production process for MediVas' subunit vaccines, which use MediVas'...
...virus infection are expected to enter the clinic this year. Financial terms were not disclosed. MediVas LLC...
BioCentury | Oct 23, 2006
Clinical News

MediVas preclinical data

...hemagglutinin (HA) and nucleoprotein (NP) from the A/Vietnam/1203/2004 virus. MediVas LLC , San Diego, Calif. Product: MediVas...
Items per page:
1 - 10 of 13